Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study

Fumie Ikeda, Kentaro Shikata, Jun Hata, Masayo Fukuhara, Yoichiro Hirakawa, Tomoyuki Ohara, Naoko Mukai, Masaharu Nagata, Daigo Yoshida, Koji Yonemoto, Motohiro Esaki, Takanari Kitazono, Yutaka Kiyohara, Toshiharu Ninomiya, Fumie Ikeda, Kentaro Shikata, Jun Hata, Masayo Fukuhara, Yoichiro Hirakawa, Tomoyuki Ohara, Naoko Mukai, Masaharu Nagata, Daigo Yoshida, Koji Yonemoto, Motohiro Esaki, Takanari Kitazono, Yutaka Kiyohara, Toshiharu Ninomiya

Abstract

Background: There is little information regarding whether the combination of Helicobacter pylori (H. pylori) antibody and serum pepsinogen (sPG), which is a marker of the degree of atrophic gastritis, has a discriminatory ability for detecting incident gastric cancer. We examined this issue in a long-term prospective cohort study of a Japanese population.

Methods: A total of 2446 Japanese community-dwelling individuals aged ≥40 years were stratified into four groups according to baseline H. pylori serological status and sPG: Group A (H. pylori[-], sPG[-]), Group B (H. pylori[+], sPG[-]), Group C (H. pylori[+], sPG[+]), and Group D (H. pylori[-], sPG[+]), and participants were followed up prospectively for 20 years.

Results: During the follow-up, 123 subjects developed gastric cancer. Compared with that in Group A, the cumulative incidence of gastric cancer was significantly increased in Groups B, C, and D, whereas no significant difference was found between Groups C and D. The multivariable-adjusted risk of gastric cancer was significantly increased in Group B (hazard ratio [HR], 4.08; 95% confidence interval [CI], 1.62-10.28) and in Groups C and D combined (HR 11.1; 95% CI, 4.45-27.46). When the multivariable model with H. pylori antibody was changed into that with the combination of H. pylori antibody and sPG, the C statistics for developing gastric cancer increased significantly (0.773 vs 0.732, P = 0.005), and the continuous net reclassification improvement value was 0.591 (P < 0.001).

Conclusions: Our findings suggest that the combination of H. pylori antibody and sPG is a useful tool for predicting the development of gastric cancer.

Figures

Figure.. 20-year cumulative incidence of gastric cancer…
Figure.. 20-year cumulative incidence of gastric cancer according to the combination of H. pylori antibody and serum pepsinogen at baseline. Groups A to D, see text for details.
*P < 0.01 vs Group A, †P = 0.53 by log rank test.

References

    1. International Agency for Research on Cancer. IRAC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 61. Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: IARC press; 1994.
    1. Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, et al. . Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama Study. Arch Intern Med. 2000;160:1962–8. 10.1001/archinte.160.13.1962
    1. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. . Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9. 10.1056/NEJMoa001999
    1. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. . Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7. 10.1016/S0140-6736(08)61159-9
    1. Walker IR, Strickland RG, Ungar B, Mackay IR. Simple atrophic gastritis and gastric carcinoma. Gut. 1971;12:906–11. 10.1136/gut.12.11.906
    1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52:6735–40.
    1. Tatsuta M, Iishi H, Nakaizumi A, Okuda S, Taniguchi H, Hiyama T, et al. . Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer. 1993;53:70–4. 10.1002/ijc.2910530114
    1. Inoue M, Tajima K, Matsuura A, Suzuki T, Nakamura T, Ohashi K, et al. . Severity of chronic atrophic gastritis and subsequent gastric cancer occurrence: a 10-year prospective cohort study in Japan. Cancer Lett. 2000;161:105–12. 10.1016/S0304-3835(00)00603-0
    1. Evans DJ Jr, Evans DG, Graham DY, Klein PD. A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology. 1989;96:1004–8.
    1. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735–9. 10.1111/j.1572-0241.2003.07410.x
    1. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245–53. 10.1007/s10120-006-0397-0
    1. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169–79. 10.1016/S0016-5085(98)70422-6
    1. Helicobacter and Cancer Collaborative Group Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347–53. 10.1136/gut.49.3.347
    1. Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, et al. . The serum pepsinogen test as a predictor of gastric cancer: the Hisayama Study. Am J Epidemiol. 2006;163:629–37. 10.1093/aje/kwj088
    1. Shikata K, Ninomiya T, Yonemoto K, Ikeda F, Hata J, Doi Y, et al. . Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol. 2012;47:669–75. 10.3109/00365521.2012.658855
    1. Plummer M, Vivas J, Fauchère JL, Del Giudice G, Peña AS, Ponzetto A, et al. . Helicobacter pylori and stomach cancer: a case-control study in Venezuela. Cancer Epidemiol Biomarkers Prev. 2000;9:961–5.
    1. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—“ABC method”. Proc Jpn Acad, Ser B, Phys Biol Sci. 2011;87:405–14. 10.2183/pjab.87.405
    1. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. . Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–43. 10.1002/ijc.11680
    1. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al. . Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764–8. 10.1136/gut.2004.055400
    1. Mizuno S, Miki I, Ishida T, Yoshida M, Onoyama M, Azuma T, et al. . Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci. 2010;55:3132–7. 10.1007/s10620-010-1154-0
    1. Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J, et al. . Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer. 2012;130:1614–9. 10.1002/ijc.26172
    1. Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, et al. . Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. Diabetologia. 1993;36:1198–203. 10.1007/BF00401066
    1. Japanese Gastric Cancer Association Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12. 10.1007/s10120-011-0041-5
    1. Shirota T, Yoshizumi E. Accuracy of nutritional survey using the simple method. Nihon Koshu Eisei Zasshi. 1990;37:100–8 (in Japanese).
    1. Resources Council of the Science and Technology Agency. Standard tables of food composition in Japan, 4th ed. Tokyo, Japan: Ministry of Finance Printing Bureau; 1982 (in Japanese).
    1. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol. 1986;124:17–27.
    1. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–49. 10.1016/j.bpg.2006.04.008
    1. Shikata K, Kiyohara Y, Kubo M, Yonemoto K, Ninomiya T, Shirota T, et al. . A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama Study. Int J Cancer. 2006;119:196–201. 10.1002/ijc.21822
    1. Shikata K, Doi Y, Yonemoto K, Arima H, Ninomiya T, Kubo M, et al. . Population-based prospective study of the combined influence of cigarette smoking and Helicobacter pylori infection on gastric cancer incidence: the Hisayama Study. Am J Epidemiol. 2008;168:1409–15. 10.1093/aje/kwn276
    1. Asano K, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, et al. . Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama Study. Int J Cancer. 2008;122:909–14. 10.1002/ijc.23191
    1. Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, et al. . Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology. 2009;136:1234–41. 10.1053/j.gastro.2008.12.045
    1. Miyazaki M, Doi Y, Ikeda F, Ninomiya T, Hata J, Uchida K, et al. . Dietary vitamin A intake and incidence of gastric cancer in a general Japanese population: the Hisayama Study. Gastric Cancer. 2012;15:162–9. 10.1007/s10120-011-0092-7
    1. Hosmer D, Lemeshow S. Applied Logistic Regression. New York: Wiley; 1989.
    1. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109–23. 10.1002/sim.1802
    1. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45. 10.2307/2531595
    1. Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21. 10.1002/sim.4085
    1. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. . Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408–16. 10.1161/CIRCULATIONAHA.109.192278
    1. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. . Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–38. 10.1097/EDE.0b013e3181c30fb2
    1. Terasawa T, Nishida H, Kato K, Miyashiro I, Yoshikawa T, Takaku R, et al. . Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One. 2014;9:e109783. 10.1371/journal.pone.0109783
    1. Watanabe M, Kato J, Inoue I, Yoshimura N, Yoshida T, Mukoubayashi C, et al. . Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis. Int J Cancer. 2012;131:2632–42. 10.1002/ijc.27514
    1. Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9. 10.1111/j.1523-5378.2011.00889.x
    1. Miwa H, Kikuchi S, Ohtaka K, Kobayashi O, Ogihara A, Hojo M, et al. . Insufficient diagnostic accuracy of imported serological kits for Helicobacter pylori infection in Japanese population. Diagn Microbiol Infect Dis. 2000;36:95–9. 10.1016/S0732-8893(99)00143-1
    1. Hattori Y, Tashiro H, Kawamoto T, Kodama Y. Sensitivity and specificity of mass screening for gastric cancer using the measurement of serum pepsinogens. Jpn J Cancer Res. 1995;86:1210–5. 10.1111/j.1349-7006.1995.tb03317.x
    1. Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Biol Markers. 2010;25:207–12.
    1. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. . Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1–20.
    1. Yoshizawa K, Oizumi H, Sasaki Y, Abe Y, Kanno N, Sakuta K, et al. . Characteristics of group A patients according to the ABC classification for gastric cancer risk screening. Nihon Shokakibyo Gakkai Zasshi. 2015;112:1492–502 (in Japanese).

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever